Last reviewed · How we verify
NCT07350369
Research on Early Warning and Diagnosis & Treatment Pathway for Micro Kidney Stones
trial testing Detect the levels of metabolites in blood and urine in Kidney Stone in 20 participants. Completed in 9 March 2026.
1 January 2026
Quick facts
| Lead sponsor | Xijing Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 1 August 2025 |
| Primary completion | 1 January 2026 |
| Estimated completion | 9 March 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Detect the levels of metabolites in blood and urine
Conditions studied
- Kidney Stone — all drugs for Kidney Stone →
Sponsor
Xijing Hospital
Who can join
Adults 18 to 70, any sex, with Kidney Stone. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Exploring abnormal metabolism in kidney stone patients and developing drugs for kidney stone treatment and their mechanisms of action.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07350369
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Stone
Currently open trials in the same condition.
- NCT06944223 — Oxalate and Citrate in Humans - Response to Citrate · NA · recruiting
- NCT07071948 — A Single-Center Clinical Study on the Efficacy and Safety of VISOR · NA · recruiting
- NCT06576661 — Evaluation of the LithoVue Elite Ureteroscope With Intra-Renal Pressure Monitoring Technology: Examination of Surgeon Be · NA · recruiting
- NCT06210009 — Effect of a DASH-Style Diet on Urinary Risk Factors for Kidney Stone Disease · NA · recruiting
- NCT07238803 — Outcomes of Using FANS With FURS in TTT of Lower Calyceal Stones. · NA · recruiting
Other Xijing Hospital trials
Trials by the same sponsor.
- NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
- NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
- NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
- NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07350369 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
- Last refreshed: 12 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07350369.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing